The 2023 CD Capital Annual Meeting was successfully held in Shanghai.

On October 19-20, the 2023 CD Capital Annual Meeting and Industry Forum, themed “Seizing the Moment, Advancing with Integrity and Innovation,” was successfully held in Shanghai. Hundreds of investors, industry guests, and entrepreneurs gathered with the Trustbridge team to exchange insights on industry trends and explore future directions.

During the meeting, CD Capital partners reviewed past investment performance and methodologies, and invited leaders of leading domestic and international medical device companies to engage in in-depth discussions about the current state and future prospects of the Chinese medical device market.

Reflecting on the development of the fund, CD Capital has gradually built a dynamic and tiered team, consistently dedicated to nurturing truth-seeking, enterprising investors with a keen sense of investment aesthetics. The fund has also developed a logical, focused, and relatively healthy portfolio of projects, yielding some returns and expecting greater future rewards. Throughout this process, CD Capital has adhered to the "Banyan Tree Theory," fostering deep cooperation with fund investors and portfolio companies. With a high proportion of co-investment and collaboration, they have formed a thriving industry ecosystem.

The medical industry is currently undergoing profound changes in both the industrial and capital environments. However, long-term and stable clinical demand, along with continuous technological innovation and supply chain development, has laid a solid foundation for the industry's long-term progress. As the healthcare payment landscape evolves, there have also been changes in the efficiency of new product approvals, the speed of payment coverage, and the accessibility of commercial channels. These shifts are greatly accelerating product iteration and category restructuring, which will provide key insights for the next phase of healthcare investment.

CD Capital believes that the interplay between technological innovation and clinical demand will be the main driving force for long-term industry progress. As the industry evolves, new investment opportunities may emerge, focusing on areas such as supply chains, manufacturing advantages, and overseas expansion. Although the faster market metabolism might raise the threshold and complexity of medical investments, the industry is bound to develop in a healthier direction over the long term.

CD Capital’s investment philosophy can be summarized in four key points:

Faith in technology: We believe technology is the fundamental driver of productivity improvement. No matter how much the market changes, technological progress remains constant and irreversible.

Cognition as the foundation: As investors, our cognition is more important than ever; only with clear understanding can we make informed choices.

Focus and restraint: CD Capital does not rely on luck or shortcuts to achieve comprehensive layouts. We dare to forgo opportunities, staying true to our direction without being swayed by trends.

Orderly evolution: In the ever-changing medical investment environment, CD Capital will continue to evolve in terms of organization, focus areas, tools, and ecosystems.

— QING TAN, Founding Partner of CD Capital

Seizing the moment, CD Capital values the experiences and knowledge accumulated along the way and will continue evolving and refining its organization to go further. Advancing with integrity, the team will adhere to its long-term investment philosophy, maintaining a stable, consistent, and rational investment approach amid market fluctuations, while expanding its fields and methodologies step by step.

With the wind in our sails, CD Capital hopes to join hands with like-minded investors to support outstanding companies, weaving a sail to navigate the seas and break through the waves together!